<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602573</url>
  </required_header>
  <id_info>
    <org_study_id>LSM-PMW</org_study_id>
    <nct_id>NCT03602573</nct_id>
  </id_info>
  <brief_title>Liver Fibrosis in Peri-menopausal Women</brief_title>
  <official_title>Nonalcoholic Fatty Liver Disease and Associated Liver Fibrosis in Peri-menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational study in a single medical center.

      The aim is to evaluate the status of fibrosis and steatosis of liver parenchyma in
      peri-menopausal women using noninvasive methods of vibration-controlled transient
      elastography (VCTE) with controlled attenuation parameter (CAP) and serum biomarkers.

      Recruitment period: 2018/08/01 to 2019/07/31

      Patient number: 200 females

      Inclusion criteria:

        1. Females, age of 46-55 years

        2. Willing and able to comply with the study requirements

        3. Willing and able to provide written informed consent to participate in the study

      Exclusion criteria:

        1. Unable to complete the noninvasive procedure of VCET and CAP

        2. Unwilling to provide written informed consent to participate in the study

      Laboratory tests and examinations:

      Baseline and two follow-up visits (every 6 months):

        1. Blood pressure

        2. BW, BH, waist circumference, BMI

        3. Complete blood cell (CBC) count

        4. Albumin, AST, ALT, alkaline phosphatase, total bilirubin, r-GT, uric acid, hsCRP

        5. Sugar (fasting), HbA1c, insulin, HOMA-IR

        6. DM lipid profiles, adiponectin, leptin

        7. Liver ultrasound, FibroScan touch 520

        8. FSH, Estrodiol (E2), LH

        9. TSH, free T4

       10. HBsAg, anti-HCV, HBV DNA, HCV RNA, HBsAg quantification, HBV genotype (if HBsAg or
           anti-HCV positive)

       11. ANA, Anti-mitochondrial antibody

       12. Review history of drug and menstruation cycles
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The impact of estrogen level on liver steatosis by FibroScan touch 520</measure>
    <time_frame>1 year</time_frame>
    <description>The association of estrogen level with the severity of liver steatosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The impact of estrogen level on liver fibrosis by FibroScan touch 520</measure>
    <time_frame>1 year</time_frame>
    <description>The association of estrogen level with the severity of liver fibrosis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Liver Fibroses</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>pre-menopause</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>post-menopause</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Females, age of 46-55 years, premenopause and postmenopause
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females, age of 46-55 years

          2. Willing and able to comply with the study requirements

          3. Willing and able to provide written informed consent to participate in the study

        Exclusion Criteria:

          1. Unable to complete the noninvasive procedure of VCET and CAP

          2. Unwilling to provide written informed consent to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Cheng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Cheng Chen, MD</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>8107</phone_ext>
    <email>yichengliver@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Cheng Chen, MD</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>8107</phone_ext>
      <email>yichengliver@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rong-Nan Chien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Cheng Chen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>Liver fibrosis</keyword>
  <keyword>Menopause</keyword>
  <keyword>Hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

